Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

27 dicembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Dec 27, 2022 | 2022, Investors, Press Releases

More details

19 dicembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Dec 19, 2022 | 2022, Investors, Press Releases

More details

12 dicembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Dec 12, 2022 | 2022, Investors, Press Releases

More details

05 dicembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Dec 5, 2022 | 2022, Investors, Press Releases

More details

Philogen to attend the Antibody Engineering & Therapeutics on December 4-8, 2022 in San Diego

Dec 3, 2022 | 2022, Past Events

Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs): A Comparative Evaluation” Please...

Philogen to attend Melanoma Bridge in Naples, 1-3 December 2022

Dec 3, 2022 | 2022, Past Events

Philogen is Sponsor at the 13th edition of Melanoma Bridge in Naples, 1-3 December 2022. For further details
« Older Entries

Recent Posts

  • 20 marzo 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen to attend the 74th Mosbacher Kolloquium in Mosbach/Baden, on March 23-25, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it